GlassScriptPhysician profile
Brantley Booth
NPI 1205527819
$4,201.08
in general payments reported to CMS, 2019-2025
19 companies · $1,925 in 2025
The $1,925 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $657 · 2024: $1,619 · 2025: $1,925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,100 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,099.59 |
| Education | $101.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $960.02 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $443.22 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $405.08 | 2023-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $327.91 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $292.65 | 2024-2025 | Auvelity |
| Alkermes, INC. | $238.34 | 2023-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $234.22 | 2023-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Lundbeck LLC | $214.96 | 2023-2025 | Rexulti |
| Indivior INC. | $214.49 | 2023-2025 | Sublocade, Perseris |
| E.R. Squibb & Sons, L.L.C. | $191.69 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $164.14 | 2023-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $118.83 | 2024-2025 | Ingrezza |
| Jazz Pharmaceuticals INC. | $110.53 | 2024 | |
| Corium, LLC | $79.78 | 2024-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $65.63 | 2024-2025 | Fanapt, Hetlioz |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $56.90 | 2023-2025 | Xelstrym, Secuado |
| Takeda Pharmaceuticals U.S.A., INC. | $46.85 | 2024-2025 | Trintellix |
| Braeburn INC. | $19.43 | 2024 | Brixadi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.41 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brantley Booth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.